GSK plc

Good afternoon and welcome to this GSK Q2 results and accelerate growth event. Today we look forward to having a good event and if you could have the agenda slide on the screen please. Just a few words on logistics before I hand over to Luke. The first thing is that we have a Q&A session for you planned at 2.45 and another one then at 4.20. After the first Q&A, you will have a short break and the event is planned to end around 5 p.m. Next slide, please. Also note the legal disclaimer on our cautionary statement regarding forward-looking statements, and I would like to add that any definitions in terms of our reporting as well as assumptions on X-ray growth can be found at the end of this deck. Lastly, if we comment on performance, any of these comments will be made at constant currency or CER unless otherwise stated. And with this, I'm delighted to hand over to Luke.

Thank you.

Welcome everyone and thanks for investing your time here to join us in person at the London Stock Exchange and on the webcast. If anyone wants photos of the South Cambridge railway station, which is the lovely orange colour, Mick Reddy has them. So we can send them to you after. Seriously, today is in two parts. The first will give you an overview of our Q2 results. Then we'll move to what is the primary focus of today, which is GSK products and our plan to grow the business and how we'll create value for both patients and shareholders. So first I'll cover the results we announced today quickly. So Q2 performance was strong. We've got continued operational momentum. with sales up 5% to more than 8.4 billion pounds. Core operating profit grew 7% and core earnings per share were up 9%. Our cash generation remains very positive at 4.3 billion pounds and our Q2 dividend is 17 pence. And we're on track in terms of our responsible business rating. In July we also closed the acquisition of New Valence. Newvalent is a precision oncology company closely aligned to our approach to VD and I'm delighted to say that this acquisition has already contributed to our portfolio with the approval of J. Datra and pre-treated ROS1 positive non-small lung cancer just last week. Looking forward, we are updating our full year 2026 guidance with sales and operating profit now towards the upper half of the range. with EPS now expected in the lower half of the range following the acquisition of Newvalent. I'll now hand over to Nina who is going to summarise how we're delivering this growth and she'll also take you through some colour on Eucala and CoPD, Exentia and Blenrep.